Literature DB >> 9784770

Mail-in questionnaire for monitoring nausea and vomiting in oncology outpatients.

S M Mullin1, D M Fletcher, L S Tyler.   

Abstract

A patient questionnaire designed to help pharmacists monitor nausea and vomiting in outpatients receiving cancer chemotherapy was studied. A 12-item questionnaire was designed by combining items from the Morrow Assessment of Nausea and Emesis (MANE) and the Functional Living Index-Emesis (FLIE). Items included number of vomiting episodes, duration of nausea, number of antiemetics, severity of nausea and vomiting, impact on quality of life, and adverse effects. The questionnaire was printed on an addressed, postage-paid card. Over an eight-week period, outpatients in a hospital's oncology clinic were asked to complete the questionnaire at home during the three days after chemotherapy. Of 48 patients asked, 42 (88%) agreed to complete the questionnaire, and 36 (86%) of these patients mailed it back to the clinic. Of the respondents, 11 reported at least one episode of vomiting, and 22 reported nausea. Thirteen respondents logged nausea ratings of 3 or higher on a 7-point scale. Twenty respondents used antiemetics. Responses given by the patients in follow-up telephone interviews did not differ significantly from the responses collected with the questionnaire. More than 90% of patients who returned the questionnaire rated it as simple to complete. Pharmacists used the self-reports of nausea or vomiting in 7 (17%) of 42 cases to recommend alternative antiemetic regimens. A mail-in questionnaire for monitoring nausea and vomiting in outpatients undergoing chemotherapy was completed and returned by a high percentage of patients and was useful to clinic pharmacists.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9784770     DOI: 10.1093/ajhp/55.18.1903

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  5 in total

1.  Skipping day 2 antiemetic medications may improve chemotherapy induced delayed nausea and vomiting control: results of two pilot phase II trials.

Authors:  Paula P Lajolo; Auro del Giglio
Journal:  Support Care Cancer       Date:  2006-09-15       Impact factor: 3.603

Review 2.  A review of patient self-report tools for chemotherapy-induced nausea and vomiting.

Authors:  Sarah G Brearley; Caroline V Clements; Alex Molassiotis
Journal:  Support Care Cancer       Date:  2008-06-13       Impact factor: 3.603

3.  Low-dose granisetron for prophylaxis of acute chemotherapy-induced nausea and vomiting: a pilot study.

Authors:  Janise Moreno; Marina Sahade; Auro del Giglio
Journal:  Support Care Cancer       Date:  2005-04-19       Impact factor: 3.603

4.  Symptom-monitoring behaviors of rural cancer patients and survivors.

Authors:  Carol J Hermansen-Kobulnicky
Journal:  Support Care Cancer       Date:  2008-12-23       Impact factor: 3.603

5.  Evaluating the effect of zingiber officinalis on nausea and vomiting in patients receiving Cisplatin based regimens.

Authors:  Fanak Fahimi; Kian Khodadad; Somayeh Amini; Farzaneh Naghibi; Jamshid Salamzadeh; Shadi Baniasadi
Journal:  Iran J Pharm Res       Date:  2011       Impact factor: 1.696

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.